Answers are grounded in this paper and cite their sources.
Investigates mutant p53 reactivation in cancer, suggesting a novel therapeutic pathway.
// Xin Yu 1,2,* , Adam R. Blanden 3,* , Sumana Narayanan 2 , Lalithapriya Jayakumar 2 , David Lubin 3 , David Augeri 4 , S. David Kimball 4 , Stewart N. Loh 3 and Darren R. Carpizo 1,2 1 Rutgers Cancer Institute of New Jersey, New Jersey 2 Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey 3 Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, New York 4 Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey * These authors contributed equally to this work Correspondence: Stewart N. Loh, email: // Darren R. Carpizo, email: // Keywords : mutant p53 reactivation, zinc-metallochaperone, mutant p53 targeted drug, thiosemicarbazone, reactive oxygen species (ROS) Received : July 29, 2014 Accepted : September 02, 2014 Published : September 03, 2014 Abstract NSC319726 (ZMC1) is a small molecule that reactivates mutant p53 by restoration of WT structure/function to the most common p53 missense mutant (p53-R175H). We investigated the mechanism by which ZMC1 reactivates p53-R175H and provide evidence that ZMC1: 1) restores WT structure by functioning as a zinc-metallochaperone, providing an optimal concentration of zinc to facilitate proper folding; and 2) increases cellular reactive oxygen species that transactivate the newly conformed p53-R175H (via post-translational modifications), inducing an apoptotic program. We not only demonstrate that this zinc metallochaperone function is possessed by other zinc-binding small molecules, but that it can reactivate other p53 mutants with impaired zinc binding. This represents a novel mechanism for an anti-cancer drug and a new pathway to drug mutant p53. Significance: We have elucidated a novel mechanism to restore wild-type structure/function to mutant p53 using small molecules functioning as zinc-metallochaperones. The pharmacologic delivery of a metal ion to restore proper folding of a mutant protein is unique to medicinal chemistry and represents a new pathway to drug mutant p53.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: